Literature DB >> 16302561

Bullous pemphigoid following therapy with an oral beta-blocker.

Adam Perry1, Joshua D Sparling, Mark Pennington.   

Abstract

A causal relationship is thought to exist between several medications and the development of bullous pemphigoid. Commonly implicated medications include furosemide, penicillins, and ibuprofen. The following is a case report of an elderly man who developed generalized bullous pemphigoid for the first time after beginning therapy with an oral beta-blocker. A literature search revealed only 2 other reports of beta-blocker associated bullous pemphigoid. As both bullous pemphigoid and beta-blockers are common in elderly patients, dermatologists may want to consider beta-blockers as potential etiological agents in the development of bullous pemphigoid.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16302561

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  5 in total

1.  Metronidazole-Induced Bullous Pemphigoid: A Case Report.

Authors:  Saibal Moitra; Sukanta Sen; Indranil Banerjee; Ayan Sikder; Prasanta Das
Journal:  J Clin Diagn Res       Date:  2015-12-01

Review 2.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

3.  A Systematic Review of Drug-Induced Pemphigoid.

Authors:  Matthew J Verheyden; Asli Bilgic; Dédée F Murrell
Journal:  Acta Derm Venereol       Date:  2020-08-17       Impact factor: 3.875

4.  Bullous pemphigoid associated with psoriasis, breast cancer and Parkinson's disease.

Authors:  Loredana Elena Stoica; V Patrascu; Rucsandra Cristina Dascalu; M E Ciurea
Journal:  Curr Health Sci J       Date:  2013-12-29

5.  Bullous Pemphigoid-like Skin Eruption during Treatment with Rivaroxaban: A Clinical Case Study.

Authors:  Cristiana Ferreira; Ana Oliveira; Antonia Furtado; Natividade Rocha; José Almeida Ribeiro
Journal:  Eur J Case Rep Intern Med       Date:  2018-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.